admin

About admin

This author has not yet filled in any details.
So far has created 315 blog entries.

2016 Fiscal Year Results

2016-annual-results

First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

20161017-tg1050-md-us-final

Next Annual General Meeting on 24 May 2016

documents

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition

link
JB. Marchand, Patricia Kleinpeter, Laetitia Fend, Christine Thioudellet, Michel Geist, Nathalie Sfrontato, Véronique Koerper, Renée Brandely, Dominique Villeval, Karola Rittner, Nathalie Silvestre, Philippe Erbs, Laurence Zitvogel, Eric Quemeneur, Xavier Preville
AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana

Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

20151223_TIME Ph2b Lancet Oncology 2015_PR EN

A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates

link
S. Leung-Theung-Long, M. Gouanvic, CA Coupet, Aurélie Ray, Emmanuel Tupin, Nathalie Silvestre, Jean-Baptiste Marchand, Doris Schmitt, Chantal Hoffmann, Murielle Klein, Philip Seegren, Maria C. Huaman, Anthony D. Cristillo, Geneviève Inchauspé
PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 (e-pub ahead of print)

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial

link
J. Nemunaitis, Z. Papai, H. Léna, G. Losonczy, F. Forget, C. Chouaid, A. Szczesna, R. Gervais, C. Ottensmeier, J. Beck, A. Kazarnowicz, V. Westeel, D. Debieuvre, A. Madroszyk, E. Felip, JM Limacher, E. Quoix
30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), November 2015, National Harbor, Maryland (TG4010 poster […]

Ladenburg Thalmann 2015 Healthcare Conference

Webcast

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

link
Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML
Vaccine. 2015 Aug 26;33(36):4548-53

Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)

link
M. Moehler, H. Chu Lee, W. Young Tak, Y. Chao, S. Woon Paik, A. Baron, G. Ungerechts, JF Blanc, M. Cho, L. Findeiss, F. Habersetzer, D. Jonker, P. Merle, L. Ruo, O. Ebert, T. Reid, R. Lencioni, A. Pelusio, M. Lusky, N. Stojkowitz, M. Hennequi, DH Kirn, JM Limacher, CJ Breitbach, M. Homerin, J. Burke, […]